Clinical Trial Detail

NCT ID NCT04003636
Title Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966) (KEYNOTE-966)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp.
Indications

intrahepatic cholangiocarcinoma

gallbladder cancer

cholangiocarcinoma

Therapies

Cisplatin + Gemcitabine

Cisplatin + Gemcitabine + Pembrolizumab

Age Groups: adult senior

No variant requirements are available.